Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention.
Researchers investigated the feasibility of using a wearable device to monitor patients with RRMM for CRS after undergoing CAR-T therapy.
PureTech Health pipeline of new medicines poised for tremendous growth
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust...
Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.